INS and hyperinsulinism: Moreover, insulinresistance, hyperinsulinemia, hyperglycemia, and chronic inflammationare the mechanisms of T2D-associated cancer occurrence and progression.3 Despite the large panel of treatment optionsfor T2D, including insulin analogues, biguanides, meglitinides, sodium-glucosecotransporter-2 inhibitors, incretin-based therapies, dipeptidyl peptidase4, α-glucosidase inhibitors, thiazolidinediones, and sulfonylureas,currently available therapies cause side effects and none of themhave shown promise in halting the underlying causes of T2D, namely,insulin resistance.4